REBOA as a bridge to haemostasis, direct suicide-risk questioning and longitudinal care for ALS risk-variant carriers.
REBOA only buys useful time when definitive haemorrhage control is already moving.
The trauma material examines REBOA as a time-limited intervention for profound non-compressible haemorrhage. The procedure may temporarily reduce distal bleeding and support central perfusion, but it is not definitive treatment. Its use only makes clinical sense when the likely bleeding territory has been identified and rapid operative, interventional radiology or pelvic-packing control is already mobilised. Zone III is the relevant target for pelvic or obstetric bleeding below the renal vessels, while zone II should be avoided.
The debate also reinforces how quickly a potential physiological advantage can be lost. Femoral access and balloon placement must not delay definitive haemostasis, and persistent hypotension after deployment should prompt immediate consideration of malposition, venous cannulation or bleeding above the balloon. Access-site injury, thrombosis, renal or limb ischaemia, compartment syndrome and reperfusion injury require active surveillance. Available trial and registry findings should therefore be interpreted alongside patient selection, operator experience, deployment success and time to source control.
Suicide prevention provides the communication and safety thread. Warning signs may be explicit, but they may also appear as shame, hopelessness, feeling trapped, withdrawal, agitation, poor sleep or increased substance use. Asking directly about suicidal thoughts does not create the idea and may reduce isolation. When imminent risk is suspected, the clinician should remain with the person, bring help to the room and reduce immediate access to medicines, sharp objects or other means where safe. Employment, social status or visible support should never substitute for an individual risk assessment.
The ALS genetics update looks beyond a one-off test result. An asymptomatic person carrying an ALS risk variant does not automatically have ALS, but the result may affect longitudinal surveillance, biomarker monitoring, prevention-trial eligibility, family planning and future access to earlier treatment. Services therefore need genetic counselling pathways, recall or registry systems, telehealth, regional partnerships and dedicated capacity for a growing carrier population.
Trauma, emergency and critical-care teams get a balanced review of resuscitative endovascular balloon occlusion of the aorta in non-compressible torso, pelvic and catastrophic obstetric haemorrhage. It frames REBOA as a temporary bridge to operative or interventional source control while examining zone selection, time-to-haemostasis, uncertain outcome evidence and serious vascular or ischaemic complications.
Nurses, emergency clinicians and mental-health teams get a practical suicide-prevention framework. Direct statements about wanting to die and subtler signs such as burden, shame, entrapment, withdrawal, agitation, insomnia and increased substance use are linked to sensitive direct questioning, immediate safety actions and rapid connection to appropriate support.
Neurology, genetics and primary-care teams get a service-planning update on asymptomatic ALS risk-variant carriers. Wider testing, gene-targeted therapies, neurofilament light chain biomarkers and prevention trials are making carrier status increasingly actionable, with implications for counselling, surveillance, family planning, trial access and specialist clinic capacity.
Before attempting REBOA, state the suspected bleeding territory, intended balloon zone and definitive destination, then ensure catheter placement does not delay theatre, interventional radiology or pelvic packing. When a patient expresses burden, shame, entrapment or hopelessness, ask directly about suicidal thoughts rather than relying on reassurance. If immediate risk is suspected, stay with the person, bring help to them and reduce access to means.
A profoundly hypotensive patient has life-threatening pelvic haemorrhage and immediate access to pelvic packing or angiographic embolisation. What is the role of REBOA, and which aortic zone matches the bleeding territory?
REBOA is a temporary bridge to definitive haemorrhage control, not definitive treatment. Zone III below the renal vessels is the relevant target for pelvic or catastrophic obstetric bleeding.
A distressed patient says they feel trapped and like a burden but has not explicitly mentioned suicide. What is the appropriate clinical response?
Ask directly and sensitively about suicidal thoughts. If imminent risk is identified, remain with the person, call help to the room and reduce immediate access to potential means where safe.
An asymptomatic adult is found to carry a pathogenic ALS risk variant. What does the result mean for ongoing care?
The result does not diagnose established ALS or guarantee future disease. It should trigger genetic counselling and structured longitudinal follow-up because surveillance, biomarkers, prevention trials, family planning and future treatment opportunities may be affected.
.svg)